Ranking 2026's Most Consequential Chemical and Pharma Ownership Changes: Braskem and Ajax Lead the Week

The chemical and pharmaceutical sectors produced two particularly notable ownership changes in 2026: IG4 Capital's takeover of control at Braskem and Eli Lilly's agreement to acquire Ajax Therapeutics. Although the transactions are fundamentally different, both show how strategic ownership changes are being used to reshape businesses around financial restructuring, technology and future growth. Braskem's transaction changes control of a major global petrochemical producer, while Ajax gives Lilly access to a promising blood-cancer drug platform.

Braskem Represents a Corporate Control Shift

IG4's transaction is significant because it replaces Novonor as Braskem's controlling shareholder after years of Novonor ownership. IG4's Shine I fund acquired approximately 50.1% of Braskem's voting shares, while Petrobras remained a major shareholder and entered the new governance structure alongside IG4. The transaction therefore represents more than a financial investment: it changes the strategic direction and governance of one of Brazil's largest chemical companies.

Ajax Represents Pipeline-Focused Pharma M&A

Lilly's Ajax transaction is different in scale and purpose. Lilly agreed to acquire Ajax for up to $2.3 billion, including upfront and milestone-based payments, gaining access to AJ1-11095, a Type II JAK2 inhibitor being developed for myelofibrosis and polycythemia vera. The deal demonstrates how pharmaceutical companies are using acquisitions to secure differentiated clinical assets rather than relying entirely on internal drug discovery.

The Financial Logic Is Completely Different

Braskem's ownership transition is closely connected to debt and corporate restructuring, making it a distressed-ownership transaction. IG4's funds used a debt-for-equity structure linked to Novonor's obligations, providing a route to acquire control while addressing creditor exposure. Ajax, by contrast, represents conventional strategic biotech M&A, where Lilly is paying for access to a developing therapeutic asset and its future commercial potential.

Why Both Deals Matter Beyond Their Individual Companies

The two transactions also illustrate different pressures facing the industries. Braskem's change of control reflects the difficult economics facing global petrochemicals, including excess capacity, weak margins and high financial leverage. Ajax reflects the opposite side of the life-sciences market, where major pharmaceutical companies continue competing for differentiated pipelines and emerging technologies. Lilly's Ajax acquisition was also part of a broader sequence of oncology-focused transactions during 2026.

The Intelligence Takeaway

Braskem and Ajax rank among the more consequential ownership stories because they demonstrate two different reasons companies change hands in 2026. Braskem represents ownership restructuring around financial pressure and industrial turnaround, while Ajax represents acquisition-driven pipeline expansion. Together, they show that ownership changes are increasingly being shaped by either the need to repair challenged industrial assets or the race to secure the next generation of high-value pharmaceutical products.